Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

257
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
257
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

308
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
308
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

287
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
287
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

274
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
274
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

748
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
748
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

249
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
249

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.

GeroScience·2026
Same author

Comment on 'Asian Reference Values for Handgrip Strength, Gait Speed, Five-Times-Sit-to-Stand Test, Muscle Mass and Calf Circumference' by Grgic et al.-The Authors' Reply.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Encouraging a move toward precision geromedicine.

Geromedicine·2026
Same author

Expected lifespan and healthspan among rural and urban individuals in Java, Indonesia.

GeroScience·2026
Same author

Physical activity and biological age measured by DNA methylation clocks: a systematic review and meta-analysis.

The lancet. Healthy longevity·2026
Same author

Baseline characteristics of the SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) multidomain dementia prevention randomized controlled trial and insights from the recruitment process.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Feb 22, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K

Towards a biological geriatric assessment.

Camilla S L Tuttle1, Andrea B Maier2

  • 1Department of Medicine and Aged Care, Royal Melbourne Hospital, University of Melbourne, Melbourne, Royal Parade, Parkville, Melbourne, Victoria 3050, Australia.

Experimental Gerontology
|October 2, 2017
PubMed
Summary

Biological age reflects individual aging differences. Combining molecular biomarkers with current geriatric assessments could enhance early detection of rapid aging processes, improving healthcare for older adults.

Keywords:
AgingBiomarkerElderlyGeriatric assessmentHallmarks

More Related Videos

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
07:18

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice

Published on: March 2, 2019

20.1K
Collecting Saliva and Measuring Salivary Cortisol and Alpha-amylase in Frail Community Residing Older Adults via Family Caregivers
08:25

Collecting Saliva and Measuring Salivary Cortisol and Alpha-amylase in Frail Community Residing Older Adults via Family Caregivers

Published on: December 18, 2013

12.2K

Related Experiment Videos

Last Updated: Feb 22, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
07:18

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice

Published on: March 2, 2019

20.1K
Collecting Saliva and Measuring Salivary Cortisol and Alpha-amylase in Frail Community Residing Older Adults via Family Caregivers
08:25

Collecting Saliva and Measuring Salivary Cortisol and Alpha-amylase in Frail Community Residing Older Adults via Family Caregivers

Published on: December 18, 2013

12.2K

Area of Science:

  • Gerontology
  • Biomarker Research
  • Molecular Biology

Background:

  • Aging is a gradual, highly individual process with significant variations in age-related diseases and functional decline.
  • Biological age, representing this variability, is not fully captured by current clinical assessments.
  • The comprehensive geriatric assessment (CGA) evaluates medical, psychological, and functional capabilities but lacks molecular aging markers.

Purpose of the Study:

  • To review current knowledge and clinical utility of potential biomarkers of aging.
  • To explore the integration of molecular aging markers into geriatric assessments.
  • To identify individuals experiencing accelerated aging processes.

Main Methods:

  • Literature review of aging biomarkers and their clinical applications.
  • Analysis of the limitations of the comprehensive geriatric assessment (CGA).
  • Discussion of the potential of combining functional measures with molecular aging indicators.

Main Results:

  • Significant inter- and intra-individual variability exists in the aging process.
  • Current CGA lacks molecular measures to accurately determine biological age.
  • Promising research suggests future clinical application of aging biomarkers.

Conclusions:

  • Integrating molecular biomarkers into CGA could significantly improve the assessment of biological age.
  • Early identification of rapid aging through combined assessments can lead to timely interventions.
  • Future clinical settings may utilize molecular biomarkers for a more comprehensive understanding of aging.